LeMaitre to Participate at Upcoming Investor Conferences in September
BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences.
LMAT - LeMaitre Vascular, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$115.00
DETAILS
HIGH:
$135.00
LOW:
$95.00
MEDIAN:
$115.00
CONSENSUS:
$115.00
UPSIDE:
43.25%
Stock News
Dividend Champion, Contender, And Challenger Highlights: Week August 16
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
GEHC or LMAT: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and LeMaitre Vascular (LMAT). But which of these two stocks presents investors with the better value opportunity right now?
LeMaitre Vascular: 31% Drawdown On $0.02 Guidance Cut
LeMaitre Vascular remains a Buy after a 31% pullback, though I have trimmed my price target to $95-$100 for year-end 2027. The Q2 2026 miss was tied to currency, export blockages, and tissue shortages. Not underlying demand. Organic sales grew 10%, and margins hit record highs. Artegraft, now 21% of sales, is LMAT's largest and fastest-growing product. It is the main factor behind margin expansion and international growth prospects.
LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
BURLINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will hold investor meetings at the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 11, 2026.
LeMaitre Vascular, Inc. (LMAT) Q2 2026 Earnings Call Transcript
LeMaitre Vascular, Inc. (LMAT) Q2 2026 Earnings Call Transcript
LeMaitre Vascular Q2 Earnings Call Highlights
LeMaitre Vascular NASDAQ: LMAT reported second-quarter 2026 results marked by 10% organic revenue growth, record operating income and continued expansion of its Artegraft product line, while foreign exchange, Middle East export delays and cardiac allograft supply constraints weighed on sales relative to management's expectations.
LeMaitre Vascular (LMAT) Q2 Earnings and Revenues Lag Estimates
LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.74 per share, missing the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.6 per share a year ago.
LeMaitre Q2 2026 Financial Results
BURLINGTON, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q2 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance.
LeMaitre Will Announce Second Quarter 2026 Earnings Results on August 4, 2026
BURLINGTON, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2026 financial results on Tuesday, August 4, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook.
We Have A Valuation Problem - May Dividend Income Report
I don't love valuation models because they rely on assumptions, and assumptions can be dangerous. But we still need to pay attention. I sold my position in BIPC not because I don't like the stock or that I'm spooked by recent movement, but rather in the optic of portfolio simplification. Since I started this portfolio in September 2017, I have received a total of $36,444.54 CAD in dividends.
Casey's & 3 More Stocks With Strong Interest Coverage to Buy Now
CASY, CLS, PNTG and LMAT stand out for strong interest coverage as borrowing costs rise, with solid sales/EPS growth estimates and big one-year gains.
LeMaitre (LMAT) is an Incredible Growth Stock: 3 Reasons Why
LeMaitre (LMAT) possesses solid growth attributes, which could help it handily outperform the market.
LeMaitre to Participate at Upcoming Investor Conferences in June
BURLINGTON, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in two upcoming investor conferences in June.
Down 17.2% in 4 Weeks, Here's Why LeMaitre (LMAT) Looks Ripe for a Turnaround
LeMaitre (LMAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
LeMaitre to Present at the Bank of America Healthcare Conference
BURLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced today that management will present at the Bank of America Healthcare Conference on Wednesday, May 13, 2026, at 5:15 PM PT.
3 Reasons Growth Investors Will Love LeMaitre (LMAT)
LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
LeMaitre (LMAT) Upgraded to Buy: Here's Why
LeMaitre (LMAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
LeMaitre Vascular, Inc. (LMAT) Q1 2026 Earnings Call Transcript
LeMaitre Vascular, Inc. (LMAT) Q1 2026 Earnings Call Transcript
LeMaitre Vascular (LMAT) Tops Q1 Earnings Estimates
LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.48 per share a year ago.
Price Targets
LeMaitre upgraded to Outperform from Market Perform at Barrington
$95.00
(was $79.00)
Barrington
LeMaitre price target raised to $135 from $110 at Lake Street
$135.00
(was $105.37)
Frank Takkinen
·
Lake Street
LeMaitre price target raised to $120 from $105 at Barrington
$120.00
(was $112.00)
Barrington
Cantor Fitzgerald Reiterates Neutral Rating on LeMaitre Vascular (LMAT)
$95.00
(was $86.96)
Ross Osborn
·
Cantor Fitzgerald
LeMaitre resumed with a Buy at Roth Capital
$108.00
(was $87.26)
Roth Capital
LeMaitre price target raised to $110 from $105 at Lake Street
$110.00
(was $91.85)
Lake Street
LeMaitre initiated with a Neutral at Cantor Fitzgerald
$96.00
(was $92.14)
Ross Osborn
·
Cantor Fitzgerald
LeMaitre price target raised to $100 from $77 at JMP Securities
$100.00
(was $85.53)
Daniel Stauder
·
JMP Securities
Stifel Upgrades LeMaitre Vascular (LMAT) to Buy
$75.00
(was $65.46)
Rick Wise
·
Stifel Nicolaus
Why LeMaitre Vascular Is A Market Leader In Core Segments: Oppenheimer Initiates With Outperform Rating
$70.00
(was $56.71)
Suraj Kalia
·
Oppenheimer